Want to see NAGE full AI Analyst Report?
NAGE Stock Chart & Stats
$4.84
--
Market closed
$4.84
--
Day’s Range― - ―
52-Week Range$3.35 - $14.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)965.61K
Market Cap
$272.38M
Enterprise Value$204.43M
Total Cash (Recent Filing)$66.55M
Total Debt (Recent Filing)$2.58M
Price to Earnings (P/E)14.1
Beta0.97
Next Earnings
Aug 12, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding79,644,325
10 Day Avg. Volume625,101
30 Day Avg. Volume965,611
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda9.55
Forecast
1Y Price Target
$11.25Price Target Upside132.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.23
Revenue Forecast (FY)$142.29M
Bulls Say, Bears Say
Bulls Say
Balance Sheet ConservatismVery low leverage and a sizable cash balance give the company durable financial flexibility to fund marketing, product rollouts, R&D and share repurchases without refinancing risk. This buffer supports execution through working-capital swings and investments over the next 2–6 months.
High Gross Margins And Profitability TurnaroundConsistently high gross margins and a return to positive net and EBIT margins indicate durable product-level economics and pricing power for the NR ingredient and finished goods. Combined with strong recent revenue expansion, this supports sustainable internal cash generation and reinvestment capacity.
Quality Differentiation And Product ExpansionA USP monograph is a structural quality credential that strengthens commercial differentiation for ingredient sales and B2B adoption. Coupled with new channels (at‑home injections, skincare, clinic IV offerings), this creates durable avenues for premium growth and partner adoption over the medium term.
Bears Say
Cash-flow VolatilityDespite positive TTM OCF and FCF, recent sharp declines and a Q1 operational cash outflow reflect inventory builds and timing with partners. Such volatility can constrain discretionary spending, make cash timing unpredictable, and raise funding needs during growth phases over the next several quarters.
Rising Operating ExpensesManagement is increasing S&M and G&A to drive e‑commerce and product launches. While strategic, sustained higher acquisition and overhead costs can compress operating margins and require continued top-line lift to justify the spend, heightening execution risk over the medium term.
Regulatory And Category Competition RiskOngoing FDA litigation and a surge of lower‑cost NMN entrants create structural uncertainty for the NAD+ category. Regulatory outcomes or aggressive competitor entry could alter market access, pricing dynamics and customer acquisition economics, posing a durable risk through the next year.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience, Inc.’s price range in the past 12 months?
Niagen Bioscience, Inc. lowest stock price was $3.35 and its highest was $14.69 in the past 12 months.
What is Niagen Bioscience, Inc.’s market cap?
Niagen Bioscience, Inc.’s market cap is $272.38M.
When is Niagen Bioscience, Inc.’s upcoming earnings report date?
Niagen Bioscience, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were Niagen Bioscience, Inc.’s earnings last quarter?
Niagen Bioscience, Inc. released its earnings results on May 06, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.068 by $0.002.
Is Niagen Bioscience, Inc. overvalued?
According to Wall Street analysts Niagen Bioscience, Inc.’s price is currently Undervalued.
Does Niagen Bioscience, Inc. pay dividends?
Niagen Bioscience, Inc. does not currently pay dividends.
What is Niagen Bioscience, Inc.’s EPS estimate?
Niagen Bioscience, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience, Inc. have?
Niagen Bioscience, Inc. has 79,644,325 shares outstanding.
What happened to Niagen Bioscience, Inc.’s price movement after its last earnings report?
Niagen Bioscience, Inc. reported an EPS of $0.07 in its last earnings report, beating expectations of $0.068. Following the earnings report the stock price went down -15.694%.
Which hedge fund is a major shareholder of Niagen Bioscience, Inc.?
Currently, no hedge funds are holding shares in NAGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (132.44% Upside)
$11.25 (132.44% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 86.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.79%
12-Months-Change
Fundamentals
Return on Equity
25.38%
Trailing 12-Months
Asset Growth
40.56%
Trailing 12-Months
Company Description
Niagen Bioscience, Inc.
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
NAGE Company Deck
NAGE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: solid revenue and net income, strong e-commerce growth, margin stability, a robust cash position, and several strategic wins (USP monograph, new product launches, scientific leadership). Offsetting items include short-term cash flow drag from inventory and timing, higher selling/marketing and G&A investments, channel volatility with some distribution partners, and intensified competition and regulatory uncertainty around NMN which is creating headwinds. Management reaffirmed full-year guidance (10%–15% growth) while electing to invest in marketing and product rollouts to drive future growth.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$11.25
▲(132.44% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
5.03% Insiders
7.86% Mutual Funds
9.08% Other Institutional Investors
69.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---